Internet Archive Scholar

P226 Inhalation characteristics with spiromax®and turbuhaler®dry powder inhalers (dpi) in healthy adults and patients with asthma or chronic obstructive pulmonary disease (copd): before and after enhanced training: Abstract P226 Table 1

H Chrystyn, W Azouz, P Chetcuti, H Hosker, D Saralaya
2013 Thorax  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (121.3 kB)
https://web.archive.org/web/20180722101517/https://thorax.bmj.com/content/thoraxjnl/68/Suppl_3/A178.2.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL. The file type is application/pdf.

pneumonia hospitalisations in patients eligible and ineligible for TORCH. There were 376 patients with COPD included from the Edinburgh pneumonia study. The 30-day mortality rate was 12.0%. 186 patients (38.0%) would have been ineligible for TORCH. After adjustment for relevant confounders, ICS use in patients classified as ineligible for TORCH was associated with increased risk of 30-day mortality (HR 1.85 95% CI 1.00-2.41). Conclusion Patients ineligible for RCTs such as TORCH are at
more » ... risk of ICS related pneumonia mortality and hospitalisation. Existing studies may therefore underestimate the true impact of ICS related pneumonia in the "real-world" setting. Abstract P224 Figure 1 .
doi:10.1136/thoraxjnl-2013-204457.378 fatcat:4k7fl6ratvcwpleybf5ejeserq
Citation

H Chrystyn, W Azouz, P Chetcuti, H Hosker, D Saralaya. "P226 Inhalation characteristics with spiromax®and turbuhaler®dry powder inhalers (dpi) in healthy adults and patients with asthma or chronic obstructive pulmonary disease (copd): before and after enhanced training: Abstract P226 Table 1." Thorax 68.Suppl 3 (2013) A178.2-A179